Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution.
Journal
Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
02
08
2021
accepted:
11
02
2022
pubmed:
2
4
2022
medline:
30
4
2022
entrez:
1
4
2022
Statut:
ppublish
Résumé
Efferocytosis, the clearance of apoptotic cells (ACs) by macrophages, is critical for tissue resolution, with defects driving many diseases. Mechanisms of efferocytosis-mediated resolution are incompletely understood. Here, we show that AC-derived methionine regulates resolution through epigenetic repression of the extracellular signal-regulated kinase 1/2 (ERK1/2) phosphatase Dusp4. We focus on two key efferocytosis-induced pro-resolving mediators, prostaglandin E
Identifiants
pubmed: 35361955
doi: 10.1038/s42255-022-00551-7
pii: 10.1038/s42255-022-00551-7
pmc: PMC9050866
mid: NIHMS1780101
doi:
Substances chimiques
Dnmt3a protein, mouse
0
Prostaglandins E
0
Transforming Growth Factor beta1
0
Methionine
AE28F7PNPL
Cyclooxygenase 2
EC 1.14.99.1
DNA Methyltransferase 3A
EC 2.1.1.37
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
444-457Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Organisme : NHLBI NIH HHS
ID : R00 HL145131
Pays : United States
Organisme : NIH HHS
ID : S10 OD030286
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL155431
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL087123
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Dalli, J. & Serhan, C. N. Pro-resolving mediators in regulating and conferring macrophage function. Front. Immunol. 8, 1400 (2017).
doi: 10.3389/fimmu.2017.01400
pubmed: 29163481
pmcid: 5671941
Doran, A. C., Yurdagul, A. Jr & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).
doi: 10.1038/s41577-019-0240-6
pubmed: 31822793
Morioka, S., Maueroder, C. & Ravichandran, K. S. Living on the edge: efferocytosis at the interface of homeostasis and pathology. Immunity 50, 1149–1162 (2019).
doi: 10.1016/j.immuni.2019.04.018
pubmed: 31117011
pmcid: 6721617
Linton, M. F. et al. Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis. Circ. J. 80, 2259–2268 (2016).
doi: 10.1253/circj.CJ-16-0924
pubmed: 27725526
pmcid: 5459487
Kojima, Y., Weissman, I. L. & Leeper, N. J. The role of efferocytosis in atherosclerosis. Circulation 135, 476–489 (2017).
doi: 10.1161/CIRCULATIONAHA.116.025684
pubmed: 28137963
pmcid: 5302553
Yurdagul, A. Jr et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518–533 e510 (2020).
doi: 10.1016/j.cmet.2020.01.001
pubmed: 32004476
pmcid: 7173557
Zhang, S. et al. Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. Cell Metab. 29, 443–456 e445 (2019).
doi: 10.1016/j.cmet.2018.12.004
pubmed: 30595481
A-Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245–258 (2009).
doi: 10.1016/j.immuni.2009.06.018
pubmed: 19646905
pmcid: 2791787
Fadok, V. A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101, 890–898 (1998).
doi: 10.1172/JCI1112
pubmed: 9466984
pmcid: 508637
Nakanishi, M. & Rosenberg, D. W. Multifaceted roles of PGE2 in inflammation and cancer. Semin. Immunopathol. 35, 123–137 (2013).
doi: 10.1007/s00281-012-0342-8
pubmed: 22996682
Funk, C. D. & FitzGerald, G. A. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 50, 470–479 (2007).
doi: 10.1097/FJC.0b013e318157f72d
pubmed: 18030055
Cheng, H., Huang, H., Guo, Z., Chang, Y. & Li, Z. Role of prostaglandin E
doi: 10.7150/thno.63396
pubmed: 34522214
pmcid: 8419039
Tang, E. H., Libby, P., Vanhoutte, P. M. & Xu, A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J. Cardiovasc. Pharmacol. 59, 116–123 (2012).
doi: 10.1097/FJC.0b013e3182244a12
pubmed: 21697732
pmcid: 3191244
Takayama, K. et al. Prostaglandin E
doi: 10.1074/jbc.M204810200
pubmed: 12215436
Gitlin, J. M. & Loftin, C. D. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovasc. Res. 81, 400–407 (2009).
doi: 10.1093/cvr/cvn286
pubmed: 18948273
Kirkby, N. S. et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS ONE 9, e98165 (2014).
doi: 10.1371/journal.pone.0098165
pubmed: 24887395
pmcid: 4041570
Yu, Z. et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl Acad. Sci. USA 109, 6727–6732 (2012).
doi: 10.1073/pnas.1115313109
pubmed: 22493243
pmcid: 3340044
Narasimha, A. et al. A novel anti-atherogenic role for COX-2–potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat. 84, 24–33 (2007).
doi: 10.1016/j.prostaglandins.2007.03.004
pubmed: 17643885
pmcid: 2701232
Yoshimura, A., Wakabayashi, Y. & Mori, T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J. Biochem. 147, 781–792 (2010).
doi: 10.1093/jb/mvq043
pubmed: 20410014
pmcid: 2912031
Mallat, Z. et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930–934 (2001).
doi: 10.1161/hh2201.099415
pubmed: 11701621
Martinez, J. et al. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc. Natl Acad. Sci. USA 108, 17396–17401 (2011).
doi: 10.1073/pnas.1113421108
pubmed: 21969579
pmcid: 3198353
Mao, Y. et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20, 4096–4106 (2014).
doi: 10.1158/1078-0432.CCR-14-0635
pubmed: 24907113
Sun, W. H. et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J. Pharmacol. Exp. Ther. 295, 447–452 (2000).
pubmed: 11046075
Mato, J. M., Martinez-Chantar, M. L. & Lu, S. C. S-adenosylmethionine metabolism and liver disease. Ann. Hepatol. 12, 183–189 (2013).
doi: 10.1016/S1665-2681(19)31355-9
pubmed: 23396728
pmcid: 4027041
Parkhitko, A. A., Jouandin, P., Mohr, S. E. & Perrimon, N. Methionine metabolism and methyltransferases in the regulation of aging and lifespan extension across species. Aging Cell 18, e13034 (2019).
doi: 10.1111/acel.13034
pubmed: 31460700
pmcid: 6826121
Quinlan, C. L. et al. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A. Nat. Chem. Biol. 13, 785–792 (2017).
doi: 10.1038/nchembio.2384
pubmed: 28553945
Finkelstein, J. D. Pathways and regulation of homocysteine metabolism in mammals. Semin. Thromb. Hemost. 26, 219–225 (2000).
doi: 10.1055/s-2000-8466
pubmed: 11011839
Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257 (1999).
doi: 10.1016/S0092-8674(00)81656-6
pubmed: 10555141
Cho, K. N. et al. Prostaglandin E
doi: 10.1074/jbc.M412722200
pubmed: 15615708
Xia, Q. et al. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death Dis. 6, e1702 (2015).
doi: 10.1038/cddis.2015.69
pubmed: 25811799
pmcid: 4385945
Xiong, W., Frasch, S. C., Thomas, S. M., Bratton, D. L. & Henson, P. M. Induction of TGF-beta1 synthesis by macrophages in response to apoptotic cells requires activation of the scavenger receptor CD36. PLoS ONE 8, e72772 (2013).
doi: 10.1371/journal.pone.0072772
pubmed: 23936544
pmcid: 3732218
Cai, B. et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab. 31, 406–421 e407 (2020).
doi: 10.1016/j.cmet.2019.11.013
pubmed: 31839486
Gerlach, B. D. et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 33, 2445–2463 e2448 (2021).
doi: 10.1016/j.cmet.2021.10.015
pubmed: 34784501
Nishi, C., Yanagihashi, Y., Segawa, K. & Nagata, S. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation. J. Biol. Chem. 294, 7221–7230 (2019).
doi: 10.1074/jbc.RA118.006628
pubmed: 30846565
pmcid: 6509494
Lang, R., Hammer, M. & Mages, J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J. Immunol. 177, 7497–7504 (2006).
doi: 10.4049/jimmunol.177.11.7497
pubmed: 17114416
Newson, J. et al. Inflammatory resolution triggers a prolonged phase of immune suppression through COX-1/mPGES-1-derived prostaglandin E2. Cell Rep. 20, 3162–3175 (2017).
doi: 10.1016/j.celrep.2017.08.098
pubmed: 28954232
pmcid: 5639146
Cai, B. et al. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl Acad. Sci. USA 113, 6526–6531 (2016).
doi: 10.1073/pnas.1524292113
pubmed: 27199481
pmcid: 4988577
Ren, Y. & Savill, J. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J. Immunol. 154, 2366–2374 (1995).
pubmed: 7532668
Tse, K. & Ley, K. Transforming growth factor-beta: transforming plaque to stability. Eur. Heart J. 34, 3684–3686 (2013).
doi: 10.1093/eurheartj/ehs228
pubmed: 22843445
Takeuch, O. & Akira, S. Epigenetic control of macrophage polarization. Eur. J. Immunol. 41, 2490–2493 (2011).
doi: 10.1002/eji.201141792
pubmed: 21952803
Roy, D. G. et al. Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming. Cell Metab. 31, 250–266.e259 (2020).
doi: 10.1016/j.cmet.2020.01.006
pubmed: 32023446
Ji, J. et al. Methionine attenuates lipopolysaccharide-induced inflammatory responses via DNA methylation in macrophages. ACS Omega 4, 2331–2336 (2019).
doi: 10.1021/acsomega.8b03571
pubmed: 30775649
pmcid: 6374979
Shikauchi, Y. et al. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol. Cell. Biol. 29, 1944–1958 (2009).
doi: 10.1128/MCB.00840-08
pubmed: 19139273
pmcid: 2655625
Guo, X. et al. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 517, 640–644 (2015).
doi: 10.1038/nature13899
pubmed: 25383530
Dai, Z., Mentch, S. J., Gao, X., Nichenametla, S. N. & Locasale, J. W. Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat. Commun. 9, 1955 (2018).
doi: 10.1038/s41467-018-04426-y
pubmed: 29769529
pmcid: 5955993
Fredman, G. et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859 (2016).
doi: 10.1038/ncomms12859
pubmed: 27659679
pmcid: 5036151
Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N. & Chan, L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595–3606 (2008).
doi: 10.1096/fj.08-112201
pubmed: 18559988
pmcid: 2537438
Takayama, K., Sukhova, G. K., Chin, M. T. & Libby, P. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ. Res. 98, 499–504 (2006).
doi: 10.1161/01.RES.0000204451.88147.96
pubmed: 16424369
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
doi: 10.1056/NEJMoa1701719
pubmed: 28636844
pmcid: 6717509
Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127, 335–353 (2020).
doi: 10.1161/CIRCRESAHA.119.316461
pubmed: 32336197
pmcid: 7367765
Toussirot, E., Bonnefoy, F., Vauchy, C., Perruche, S. & Saas, P. Mini-Review: The administration of apoptotic cells for treating rheumatoid arthritis: current knowledge and clinical perspectives. Front. Immunol. 12, 630170 (2021).
doi: 10.3389/fimmu.2021.630170
pubmed: 33717160
pmcid: 7950318
Mevorach, D. et al. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. Biol. Blood Marrow Transpl. 20, 58–65 (2014).
doi: 10.1016/j.bbmt.2013.10.010
Zhang, Z. et al. Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE
doi: 10.1016/j.ebiom.2019.06.016
pubmed: 31248835
pmcid: 6642220
Pujol-Autonell, I. et al. Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity. PLoS ONE 8, e63296 (2013).
doi: 10.1371/journal.pone.0063296
pubmed: 23691013
pmcid: 3654963
Fourgeaud, L. et al. TAM receptors regulate multiple features of microglial physiology. Nature 532, 240–244 (2016).
doi: 10.1038/nature17630
pubmed: 27049947
pmcid: 5358512
Kasikara, C. et al. Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis. J. Clin. Invest. e145275 (2021).